Human epidermal growth factor receptor 2 (HER2/ErbB2/neu) has gained tremendous importance as a biomarker in diagnostics and a target in the therapy of breast cancers, but also in gastric and gastroesophageal cancers, over the past decade1. This evidence concerns the gene ERBB2 and breast carcinoma.